Research Open Access
Like 0



Georgia has adopted the World Health Organization European Region’s and global goals to eliminate viral hepatitis. A nationwide serosurvey among adults in 2015 showed 2.9% prevalence for hepatitis B virus (HBV) surface antigen (HBsAg) and 25.9% for antibodies against HBV core antigen (anti-HBc). HBV infection prevalence among children had previously not been assessed.


We aimed to assess HBV infection prevalence among children and update estimates for adults in Georgia.


This nationwide cross-sectional serosurvey conducted in 2021 among persons aged ≥ 5 years used multi-stage stratified cluster design. Participants aged 5–20 years were eligible for hepatitis B vaccination as infants. Blood samples were tested for anti-HBc and, if positive, for HBsAg. Weighted proportions and 95% confidence intervals (CI) were calculated for both markers.


Among 5–17 year-olds (n = 1,473), 0.03% (95% CI: 0–0.19) were HBsAg-positive and 0.7% (95% CI: 0.3–1.6) were anti-HBc-positive. Among adults (n = 7,237), 2.7% (95% CI: 2.3–3.4) were HBsAg-positive and 21.7% (95% CI: 20.4–23.2) anti-HBc-positive; HBsAg prevalence was lowest (0.2%; 95% CI: 0.0–1.5) among 18–23-year-olds and highest (8.6%; 95% CI: 6.1–12.1) among 35–39-year-olds.


Hepatitis B vaccination in Georgia had remarkable impact. In 2021, HBsAg prevalence among children was well below the 0.5% hepatitis B control target of the European Region and met the ≤ 0.1% HBsAg seroprevalence target for elimination of mother-to-child transmission of HBV. Chronic HBV infection remains a problem among adults born before vaccine introduction. Screening, treatment and preventive interventions among adults, and sustained high immunisation coverage among children, can help eliminate hepatitis B in Georgia by 2030.


Article metrics loading...

Loading full text...

Full text loading...



  1. Ott JJ, Stevens GA, Groeger J, Wiersma ST. Global epidemiology of hepatitis B virus infection: new estimates of age-specific HBsAg seroprevalence and endemicity. Vaccine. 2012;30(12):2212-9.  https://doi.org/10.1016/j.vaccine.2011.12.116  PMID: 22273662 
  2. Goldstein ST, Zhou F, Hadler SC, Bell BP, Mast EE, Margolis HS. A mathematical model to estimate global hepatitis B disease burden and vaccination impact. Int J Epidemiol. 2005;34(6):1329-39.  https://doi.org/10.1093/ije/dyi206  PMID: 16249217 
  3. Butsashvili M, Tsertsvadze T, McNutt LA, Kamkamidze G, Gvetadze R, Badridze N. Prevalence of hepatitis B, hepatitis C, syphilis and HIV in Georgian blood donors. Eur J Epidemiol. 2001;17(7):693-5.  https://doi.org/10.1023/A:1015566132757  PMID: 12086085 
  4. Kuniholm MH, Mark J, Aladashvili M, Shubladze N, Khechinashvili G, Tsertsvadze T, et al. Risk factors and algorithms to identify hepatitis C, hepatitis B, and HIV among Georgian tuberculosis patients. Int J Infect Dis. 2008;12(1):51-6.  https://doi.org/10.1016/j.ijid.2007.04.015  PMID: 17644020 
  5. Bouscaillou J, Champagnat J, Luhmann N, Avril E, Inaridze I, Miollany V, et al. Hepatitis C among people who inject drugs in Tbilisi, Georgia: an urgent need for prevention and treatment. Int J Drug Policy. 2014;25(5):871-8.  https://doi.org/10.1016/j.drugpo.2014.01.007  PMID: 24529802 
  6. Kasradze A, Shadaker S, Kuchuloria T, Gamkrelidze A, Nasrullah M, Gvinjilia L, et al. The burden and epidemiology of hepatitis B and hepatitis D in Georgia: findings from the national seroprevalence survey. Public Health. 2020;185:341-7.  https://doi.org/10.1016/j.puhe.2020.06.024  PMID: 32738575 
  7. Razavi-Shearer D, Gamkrelidze I, Nguyen MH, Chen D-S, Van Damme P, Abbas Z, et al. Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study. Lancet Gastroenterol Hepatol. 2018;3(6):383-403.  https://doi.org/10.1016/S2468-1253(18)30056-6  PMID: 29599078 
  8. Hepatitis B vaccines: WHO position paper – July 2017. Wkly Epidemiol Rec. 2017;92(27):369-92. French. PMID: 28685564 
  9. World Health Organization (WHO). Hepatitis B vaccination coverage – Georgia. Geneva: WHO. [Accessed: 2 Jul 2023]. Available from: https://immunizationdata.who.int/pages/coverage/hepb.html?CODE=GEO&ANTIGEN=&YEAR=
  10. Khetsuriani N, Mosina L, Van Damme P, Mozalevskis A, Datta S, Tohme RA. Progress Toward Hepatitis B Control - World Health Organization European Region, 2016-2019. MMWR Morb Mortal Wkly Rep. 2021;70(30):1029-35. PMID: 34324482 
  11. Rostropovich-Vishnevskaya Foundation (RVF). Hepatitis B Catch-up vaccination program to protect at-risk healthcare workers, medical students and adolescents. Washington: RVF. [Accessed: 2 Jul 2023]. Available from: https://rostropovich.org/en/hepatitis-b-catch-up-vaccination-program-to-protect-at-risk-healthcare-workers-medical-students-and-adolescents
  12. Ministry of Internally Displaced Persons from the Occupied Territories, Labour, Health and Social Affairs of Georgia (MOH). Decree N°01-6/N on approval of the list of occupations subject to mandatory preventive immunizations. Tbilisi: MOH; 2019. Georgian. Available from: https://www.moh.gov.ge/uploads/files/2019/Failebi/30.01.2019-2.pdf
  13. World Health Organization Regional Office for Europe (WHO/Europe). Action plan for the health sector response to viral hepatitis in the WHO European Region. Copenhagen: WHO/Europe; 2017. Available from: https://apps.who.int/iris/handle/10665/344154
  14. World Health Organization (WHO). Global health sector strategy on viral hepatitis 2016-2021. Geneva: WHO; 2016. Available from: https://www.who.int/publications/i/item/WHO-HIV-2016.06
  15. World Health Organization (WHO). Global guidance on criteria and processes for validation: elimination of mother-to-child transmission of HIV, syphilis and hepatitis B virus. Geneva: WHO, 2021. https://www.who.int/publications/i/item/9789240039360
  16. United Nations (UN). Sustainable Development Goals. 3. Ensure healthy lives and promote well-being for all at all ages. New York: United Nations. [Accessed: 12 Jul 2023]. Available from: https://sdgs.un.org/goals/goal3
  17. Hagan LM, Kasradze A, Salyer SJ, Gamkrelidze A, Alkhazashvili M, Chanturia G, et al. Hepatitis C prevalence and risk factors in Georgia, 2015: setting a baseline for elimination. BMC Public Health. 2019;19(S3) Suppl 3;480.  https://doi.org/10.1186/s12889-019-6784-3  PMID: 32326913 
  18. Averhoff F, Shadaker S, Gamkrelidze A, Kuchuloria T, Gvinjilia L, Getia V, et al. Progress and challenges of a pioneering hepatitis C elimination program in the country of Georgia. J Hepatol. 2020;72(4):680-7.  https://doi.org/10.1016/j.jhep.2019.11.019  PMID: 31811882 
  19. Chkhartishvili N, Holban T, Simonović Babić J, Alexiev I, Matičič M, Kowalska J, et al. State of viral hepatitis care in 16 countries of Central and Eastern European Region. Cent Eur J Public Health. 2019;27(3):212-6.  https://doi.org/10.21101/cejph.a5486  PMID: 31580556 
  20. Musabaev E, Estes C, Sadirova S, Bakieva S, Brigida K, Dunn R, et al. Viral hepatitis elimination challenges in low- and middle-income countries-Uzbekistan Hepatitis Elimination Program (UHEP). Liver Int. 2023;43(4):773-84.  https://doi.org/10.1111/liv.15514  PMID: 36606729 
  21. Dunn R, Musabaev E, Razavi H, Sadirova S, Bakieva S, Razavi-Shearer K, et al. Progress toward hepatitis B and hepatitis C elimination using a catalytic funding model - Tashkent, Uzbekistan, December 6, 2019-March 15, 2020. MMWR Morb Mortal Wkly Rep. 2020;69(34):1161-5.  https://doi.org/10.15585/mmwr.mm6934a3  PMID: 32853186 
  22. Nersesov A, Gusmanov A, Crape B, Junusbekova G, Berkinbayev S, Jumabayeva A, et al. Seroprevalence and risk factors for hepatitis B and hepatitis C in three large regions of Kazakhstan. PLoS One. 2021;16(12):e0261155.  https://doi.org/10.1371/journal.pone.0261155  PMID: 34914773 
  23. Amerzhanov D, Suleimenova I, Davlidova S, Nugmanova Z, Ali S. HBV prevention and treatment in countries of Central Asia and the Caucasus. Viruses. 2020;12(10):11112.  https://doi.org/10.3390/v12101112  PMID: 33008101 
  24. Davlidova S, Haley-Johnson Z, Nyhan K, Farooq A, Vermund SH, Ali S. Prevalence of HIV, HCV and HBV in Central Asia and the Caucasus: A systematic review. Int J Infect Dis. 2021;104:510-25.  https://doi.org/10.1016/j.ijid.2020.12.068  PMID: 33385583 
  25. Khetsuriani N, Tishkova F, Jabirov S, Wannemuehler K, Kamili S, Pirova Z, et al. Substantial decline in hepatitis B virus infections following vaccine introduction in Tajikistan. Vaccine. 2015;33(32):4019-24.  https://doi.org/10.1016/j.vaccine.2015.05.092  PMID: 26072015 
  26. Sergeeva T, Ivanchuk I. Hepatitis B in Ukraine: Descriptive epidemiology and burden (based on the analysis of data from various sources). Kyiv: Ministry of Health of Ukraine; 2018. 136 p. Ukrainian.
  27. Streinu-Cercel A, Oana Săndulescu O, Neguț AC, et al. Romanian nationwide screening for infection with HIV and hepatitis B and C viruses. Proceedings of The 8th Romanian National HIV/AIDS Congress and The 3rd Central European HIV Forum Sibiu, Romania. 5-7 May 2016. BMC Infect Dis. 2016;16(Suppl 3):O15.
  28. Gamkrelidze A, Shadaker S, Tsereteli M, Alkhazashvili M, Chitadze N, Tskhomelidze I, et al. Nationwide hepatitis C serosurvey and progress towards HCV elimination in the country of Georgia, 2021. J Infect Dis. 2023;jiad064.  https://doi.org/10.1093/infdis/jiad064  PMID: 36932731 
  29. World Health Organization (WHO). Documenting the impact of hepatitis B immunization: best practices for conducting a serosurvey. Geneva: WHO; 2011. Available from: http://www.who.int/publications/i/item/documenting-the-impact-of-hepatitis-b-immunization
  30. World Health Organization (WHO). Guidelines for the prevention, care and treatment of persons with chronic hepatitis B infection. Geneva: WHO; 2015. Available from: https://https://www.who.int/publications/i/item/9789241549059
  31. National Statistics Office of Georgia (GEOSTAT). Population as of 1 January by age and sex by single years of age. Tbilisi: GEOSTAT. [Accessed: 2 Jul 2023]. Available from: https://www.geostat.ge/en/modules/categories/41/population
  32. World Health Organization Regional Office for Europe (WHO/Europe). Twenty-second meeting of the European Technical Advisory Group of Experts on Immunization (ETAGE): Hybrid meeting hosted in Copenhagen, Denmark, 6–7 December 2022. Copenhagen: WHO/Europe; 2023. Available from: https://www.who.int/europe/publications/i/item/WHO-EURO-2023-7368-47134-68979
  33. World Health Organization (WHO). Triple elimination initiative of mother-to-child transmission of HIV, syphilis and hepatitis B: Validation process & tools. Geneva: WHO. [Accessed: 6 Jul 2023]. Available from: https://www.who.int/initiatives/triple-elimination-initiative-of-mother-to-child-transmission-of-hiv-syphilis-and-hepatitis-b/validation/process-and-tools
  34. World Health Organization Regional Office for Europe (WHO/Europe). Mitigating the impact of COVID-19 on control of vaccine-preventable diseases: a health risk management approach focused on catch-up vaccination. Copenhagen: WHO/Europe; 2020. from: https://https://www.who.int/europe/publications/i/item/WHO-EURO-2020-1086-40832-55187
  35. Bloch EM, Kipiani E, Shadaker S, Alkhazashvili M, Gvinjilia L, Kuchuloria T, et al. Blood transfusion safety in the country of Georgia: collateral benefit from a national hepatitis C elimination program. Transfusion. 2020;60(6):1243-52.  https://doi.org/10.1111/trf.15815  PMID: 32542715 
  36. Beselia A, Gegenava V, Kirtadze I, Mgebrishvili T, Otiashvili D, Razmadze M, et al. Drug situation in Georgia 2018. Tbilisi, Georgia 2018. Tbilisi: Alternative Georgia; 2019. Available from: https://altgeorgia.ge/media/uploads/drug-situation-in-georgia-2018-summary.pdf
  37. Deryabina A, Lyman M, Yee D, Gelieshvilli M, Sanodze L, Madzgarashvili L, et al. Core components of infection prevention and control programs at the facility level in Georgia: key challenges and opportunities. Antimicrob Resist Infect Control. 2021;10(1):39.  https://doi.org/10.1186/s13756-020-00879-3  PMID: 33627194 
  38. Nersesov A, Gusmanov A, Crape B, Junusbekova G, Berkinbayev S, Jumabayeva A, et al. Seroprevalence and risk factors for hepatitis B and hepatitis C in three large regions of Kazakhstan. PLoS One. 2021;16(12):e0261155.  https://doi.org/10.1371/journal.pone.0261155  PMID: 34914773 
  39. Poethko-Müller C, Zimmermann R, Hamouda O, Faber M, Stark K, Ross RS, et al. [Epidemiology of hepatitis A, B, and C among adults in Germany: results of the German Health Interview and Examination Survey for Adults (DEGS1)]. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2013;56(5-6):707-15.  https://doi.org/10.1007/s00103-013-1673-x  PMID: 23703489 
  40. Musabaev E, Estes C, Sadirova S, Bakieva S, Brigida K, Dunn R, et al. Viral hepatitis elimination challenges in low- and middle-income countries-Uzbekistan Hepatitis Elimination Program (UHEP). Liver Int. 2023;43(4):773-84.  https://doi.org/10.1111/liv.15514  PMID: 36606729 
  41. World Health Organization (WHO). Guidelines for the care and treatment of persons diagnosed with chronic hepatitis C virus infection. Geneva: WHO, 2018. Available from: https://www.who.int/publications/i/item/9789241550345
  42. Shilton S, Markby J, Japaridze M, Chihota V, Shadaker S, Gvinjilia L, et al. Feasibility and effectiveness of HCV viraemia testing at harm reduction sites in Georgia: A prospective three-arm study. Liver Int. 2022;42(4):775-86.  https://doi.org/10.1111/liv.15191  PMID: 35129278 
  43. Butsashvili M, Kamkamidze G, Kajaia M, Gvinjilia L, Kuchuloria T, Khonelidze I, et al. Integration of hepatitis C treatment at harm reduction centers in Georgia-Findings from a patient satisfaction survey. Int J Drug Policy. 2020;84:102893.  https://doi.org/10.1016/j.drugpo.2020.102893  PMID: 32739613 
  44. Butsashvili M, Abzianidze T, Kamkamidze G, Gulbiani L, Gvinjilia L, Kuchuloria T, et al. Barriers of linkage to HCV viremia testing among people who inject drugs in Georgia. Subst Abuse Treat Prev Policy. 2022;17(1):23.  https://doi.org/10.1186/s13011-022-00438-6  PMID: 35346265 

Data & Media loading...

Supplementary data

Submit comment
Comment moderation successfully completed
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error